Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy

Giuseppe Lippi; Massimo Franchini; Giovanni Targher

doi:10.1160/TH07-02-0108

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2007; 97(06): 1059-1060
DOI: 10.1160/TH07-02-0108

Letters to the Editor

Schattauer GmbH

Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy

Authors

Giuseppe Lippi

¹Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Verona, Italy
Massimo Franchini

²Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
Giovanni Targher

³Sezione di Endocrinologia e Malattie del Metabolismo, Dipartimento di Scienze Biomediche e Chirurgiche, Università degli Studi di Verona, Italy

Abstract

Full Text

References

References
1 Fateh-Moghadam S, Gawaz M. Retinal vein occlusion disease and platelet activation: Will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future?. Thromb Haemost 2007; 97: 169-170.
2 Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
3 Mandell MA, Sharma S. Ophthaproblem. Central retinal vein obstruction. Can Fam Physician 2005; 51: 1627.
4 Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward?. Br J Ophthalmol 2006; 90: 627-639.
5 Mester U. Surgical approach to retinal vein occlusion. Klin Monatsbl Augenheilkd 2005; 222: 299-308.
6 Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward?. Br J Ophthalmol 2006; 90: 627-639.
7 Walsh PN, Goldberg RE, Tax RL. et al Platelet coagulant activities and retinal vein thrombosis. Thromb Haemost 1977; 38: 399-406.
8 Leoncini G, Bruzzese D, Signorello MG. et al Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007; 97: 218-227.
9 Mansour AM, Walsh JB, Henkind P. Central retinal vein occlusion and diabetes mellitus. Thromb Haemost 1987; 58: 1088.
10 Albisinni R, Coppola A, Loffredo M. et al Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-703.
11 Prisco D, Bertini L, Marcucci R. et al Retinal vein occlusions: diseases for the internist?. Ann Ital Med Int 2000; 15: 75-84.
12 Marcucci R, Bertini L, Giusti B. et al Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-776.
13 Janssen MC, den Heijer M, Cruysberg JR. et al Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
14 Meschengieser SS. Retinal vein occlusion: a venous complication in an „arterial“ patient?. Thromb Haemost 2005; 93: 1013.
15 Arsene S, Delahousse B, Regina S. et al Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101-106.
16 Linna T, Ylikorkala A, Kontula K. et al Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-216.
17 D'Angelo A, Tavola A, Fermo I. et al Moderate hyperhomocysteinemia and central retinal vein occlusion. Thromb Haemost 2002; 87: 1078-1079.
18 Gori AM, Marcucci R, Fatini C. et al Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004; 92: 54-60.
19 Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003; 40: 1-42.
20 Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system?. Thromb Haemost 1990; 63: 331-335.
21 Bandello F, Vigano D'Angelo S, Parlavecchia M. et al Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39-43.
22 Lip PL, Blann AD, Jones AF. et al Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998; 12: 245-251.
23 Murata M, Saito T, Takahashi S. et al Plasma lipoprotein( a) levels are high in patients with central retinal artery occlusion. Thromb Res 1998; 91: 169-175.
24 Ribeaudeau-Saindelle F, Glacet-Bernard A, Lelong F. et al Retinal vein occlusion and lipoprotein (a). J Fr Ophtalmol 1998; 21: 245-250.
25 Glueck CJ, Bell H, Vadlamani L. et al Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-49.
26 Wong TY, Larsen EK, Klein R. et al Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005; 112: 540-547.
27 Kagawa A, Azuma H, Akaike M. et al Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274: 34111-34115.
28 Cushing GL, Gaubatz JW, Nava ML. et al Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
29 Akaike M, Azuma H, Kagawa A. et al Effect of aspirin treatment on serum concentrations of lipoprotein( a) in patients with atherosclerotic diseases. Clin Chem 2002; 48: 1454-1459.
30 Discepolo W, Wun T, Berglund L. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006; 35: 314-321.
31 Milionis HJ, Mikhailidis DP, Winder AF. Platelets and lipoprotein (a): a brief overview of their role in the pathogenesis of atherothrombosis. Platelets 1999; 10: 277-284.
32 Rand ML, Sangrar W, Hancock MA. et al Apolipoprotein( a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscl Thromb Vasc Biol 1998; 18: 1393-1.